Blair William & Co. IL Sells 549 Shares of Jazz Pharmaceuticals PLC $JAZZ

Blair William & Co. IL cut its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 21.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,006 shares of the specialty pharmaceutical company’s stock after selling 549 shares during the period. Blair William & Co. IL’s holdings in Jazz Pharmaceuticals were worth $213,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 63.7% during the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 395 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Jazz Pharmaceuticals by 5.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $538,000 after buying an additional 232 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Jazz Pharmaceuticals during the first quarter worth $1,888,000. State of Alaska Department of Revenue raised its position in Jazz Pharmaceuticals by 0.6% in the 1st quarter. State of Alaska Department of Revenue now owns 33,083 shares of the specialty pharmaceutical company’s stock valued at $4,106,000 after buying an additional 190 shares during the last quarter. Finally, Johnson Investment Counsel Inc. lifted its stake in Jazz Pharmaceuticals by 5.1% during the 1st quarter. Johnson Investment Counsel Inc. now owns 20,790 shares of the specialty pharmaceutical company’s stock valued at $2,581,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on JAZZ shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 target price for the company. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group increased their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 11,500 shares of company stock worth $1,525,280 in the last three months. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $136.06 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The stock has a fifty day simple moving average of $128.20 and a two-hundred day simple moving average of $116.00. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a market cap of $8.25 billion, a price-to-earnings ratio of -20.22, a price-to-earnings-growth ratio of 8.35 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.